medigraphic.com

2014, Number 3

<< Back Next >>

Enf Infec Microbiol 2014; 34 (3)

Perinatal and reproductive repercussion of the infection by Chlamydia trachomatis and Mycoplasma

García OA, Cardoso YG, Limón RAE, Casanova RG, Ortiz IFJ, Reyna FJ

Language: Spanish
References: 51
Page: 78-85
PDF size: 173.65 Kb.


ABSTRACT

It has become clear that infertility sometimes preceded by a genital infection, identifying Chlamydia trachomatis and Mycoplasma as responsible for complications in the reproductive area and perinatal health. Current treatment recommendations are reviewed and the focus for those who do not improve with initial treatment, and to address specific problems such as the treatment of a woman with recurrent culture positive for Ct or Mycoplasma, treatment during pregnancy, risk newborns infected and the risk of reinfection, all within a reproductive and perinatal plane.


REFERENCES

  1. Stamm WE. “Chlamydia trachomatis infections of the adult”. En: Sexually Transmitted Diseases, 4th Edition, Holmes KK, Sparling PF, Mardh PA, et al (Eds), McGraw- Hill, San Francisco, 1999, 407-427.

  2. Black CM: “Current methods of laboratory diagnosis of Chlamydia trachomatis infections”. Clin Microbiol Rev 1997;10:160-184.

  3. Ohm MJ, Galask RP: “Bacterial flora of the cervix from 100 prehysterectomy patients”. Am J Obstet Gynecol 1973:117:1053-1055.

  4. Reyna FJ, “Epidemiologìa de las infecciones de Transmisiòn Sexual” En: Infecciones de Transmisión Sexual, Casanova RG, Ortiz IFJ, Reyna FJ (ed) México DF, Editorial Alfil, 17-26.

  5. Casanova RG “Infecciòn Genital por Chlamydia trachomatis” En: Infecciones de Transmisión Sexual, Casanova RG, Ortiz IFJ, Reyna FJ (ed) México DF, Editorial Alfil, 17-26.

  6. Homes K, Sparling F. Sexually Trasnmitted diseases; 3a ed., San Francisco, MacGrawHill, 1999.

  7. Da Vanzzo J: “Health consequences of contraceptive use and reproductive patterns”. JAMA 1991;265:2692-2696. Mosher WD, Aral SD: “Testing for sexually transmitted

  8. diseases among women of reproductive age”. Fam Plann Perpsect 1991;23:216-221.

  9. Maniloff J, Mc Elhaney RN, Finch LR, Baseman J (eds.): Mycoplasma: molecular biologu and pathogenesis, Washington, American Society for Mycorbiology, 1992:457-471.

  10. Canto-de Cetina T, Polanco Reyes L, Fernàndez González V, Ruiz García S. “Chlamyidia trcachomatis infection in users of two planning clinics”. Salud Pública Mex 2003;45 suppl 5:S657-S661.

  11. Guerra IF, Flores MS, Arteaga TG, Zamora RA, Lopez HM, Ortiz IFJ. “Risk factors and reproductive sequelae associated with Chlamydia trachomatis infection in fertile women”. Salud Pública Mex 2002;45; suppl5:S672-S680.

  12. Cravioto MC, Matamoros O, Villalobos ZY, Peña O, Garcia LE, Martinez M, Castelo J, Sifuentes OJ. “Prevalence of antibodies against Chlamydia trachomatis and Neisseria gonorrhoeae in Mexican populations”. Salud Pública Mex 2003;45 suppl 5:S681-S689.

  13. Ramírez IC; Casanova RG; Menocal TG, Ortiz IFJ; Ahued AR. “Prevalencia de la infección cervicovaginal por Micoplasma hominis y Ureaplasma urealyticum en pacientes ginecológicas del Instituto Nacional de Perinatología”. Enfermedades Infecciosas y Microbiología 2004;24.

  14. Cohen CR, Mugo NR, Astete SG, Odondo R, Manhart LE, Kiehlbauch JA, Stamm WE, Waiyaki PG, Totten PA. “Detection of Mycoplasma genitalium in women with laparoscopically diagnosed acute salpingitis”. Sex Transm Infect. 2005 Dec;81(6):463-6.84 Enfermedades Infecciosas y Microbiología, vol. 34, núm. 3, julio-septiembre 2014 ARTÍCULOS ORIGINALES ENF INF MICROBIOL 2014 34 (3): 78-85

  15. Cheng W, Shivshankar P, Li Z, Chen L, Yeh IT, Zhong G. “Caspase 1 contributes to Chlamydia trachomatis-induced upper urogenital tract inflammatory pathologies without affecting the infection course” Infect Immun. 2007 Nov 19 Epub ahead of print.

  16. Chandler DK, Razin S, Stephens EB, Harasawa R, Barile MF “Genomic and phenotypic analyses of Mycoplasma pneumoniae strains”. Infect Immun. 1982 Nov;38(2):604-9.

  17. Peltier MR, Freeman AJ, Mu HH, Cole BC “Characterization of the macrophage-stimulating activity from Ureaplasma urealyticum”, Am J Reprod Immunol. 2007 Mar;57(3):186-92.

  18. Roan NR, Starnbach MN “Immune-mediated control of Chlamydia infection” Cell Microbiol. 2008 Jan;10(1):9-

  19. Epub 2007 Nov 2. Guerra-Infante FM, Tapia-Yáñez JR, López-Hurtado M, Flores-Medina S, Díaz-García FJ. “Chlamydia trachomatis infection in men and its association with gynecologic alterations in their sexual partners”, Rev Invest Clin. 2005 May-Jun;57(3):406-14.

  20. Trentmann O, Horn M, Van Scheltinga AC, Neuhaus HE, Haferkamp I. “Enlightening energy parasitism by analysis of an ATP/ADP transporter from chlamydiae”. PLoS Biol. 2007 Sep;5(9):e231.

  21. Askienazy-Elbhar M. “Male genital tract infection: the point of view of the bacteriologist”, Gynecol Obstet Fertil. 2005 Sep;33(9):691-7.

  22. Mpiga P, Mansour S, Morisset R, Beaulieu R, Ravaoarinoro M. “Sustained interleukin-6 and interleukin-8 expression following infection with Chlamydia trachomatis serovar L2 in a HeLa/THP-1 cell co-culture model”. Scand J Immunol. 2006 Mar;63(3):199-207

  23. Betsou F, Borrego MJ, Guillaume N, Catry MA, Romão S, Machado-Caetano JA, Sueur JM, Mention J, Faille N, Orfila J “Cross-reactivity between Chlamydia trachomatis heat shock protein 10 and early pregnancy factor”, Clin Diagn Lab Immunol. 2003 May;10(3):446-50.

  24. Azenabor AA, Kennedy P, Balistreri S “Chlamydia trachomatis infection of human trophoblast alters estrogen and progesterone biosynthesis: an insight into role of infection in pregnancy sequelae”, Int J Med Sci. 2007 Sep 6;4(4):223-31.

  25. Gómez R, Romero R, Nien JK, Medina L, Carstens M, Kim YM, Espinoza J, Chaiworapongsa T, González R, Iams JD, Rojas I. “Antibiotic administration to patients with preterm premature rupture of membranes does not eradicate intra-amniotic infection”. J Matern Fetal Neonatal Med. 2007 Feb;20(2):167-73.

  26. Onderdonk AB, Delaney ML, DuBois AM, Allred EN, Leviton A; “Extremely Low Gestational Age Newborns (ELGAN) Study Investigators. Detection of bacteria in placental tissues obtained from extremely low gestational age neonates”. Am J Obstet Gynecol. 2008 Jan;198(1):110.e1-7.

  27. Romero R, Garite TJ. “Twenty percent of very preterm neonates (23-32 weeks of gestation) are born with bacteremia caused by genital Mycoplasma”. Am J Obstet Gynecol. 2008 Jan;198(1):1-3.

  28. Hammerschlag M.R. “Chlamydia trachomatis and Chlamydia pneumoniae infections in children and adolescents”. Pediatr Rev 2004;25:43-51.

  29. Remington JS, Klein JO, Wilson CB, Baker CJ. Infectius diseases of the fetus and newborn infant. 2006. Ed. Elsevier Saunders. 6ta edición, 385-92.

  30. Guerra-Infante FM, López-Hurtado M. “Mecanismos inespecíficos en la eliminación de Chlamydia trachomatis. Aspectos microbiológicos y fagocitosis”. Perinatol Reprod humana 1999, 13: fasiculo 3.

  31. Schachter J: “Chlamydial infections”. West J Med 1990 Nov; 153:523-534.

  32. Beatty WL, Morrison RP, Byrne GI. “Persistent Chlamydiae: from Cell Culture to a Paradigm Chlamydial Pathogenesis”. Microbiol Rev. 1994;58:686-699.

  33. Gencay M, Koskiniemi M, Fellman V, Ämmälä P, Vaheri A, Puolakkainen M. “Chlamydia trachomatis infection in mothers with preterm delivery and in their newborn infants”. APMIS 2001;109:636–40.

  34. Vaz FAC, Ceccon MEJ, Diniz EMA. “Chlamydia trachomatis infection in neonatal period. Clinical and Laboratorial aspects. Experience of ten years: 1987-1998”. Rev Ass Med Brasil 1999; 45: 303-11.

  35. Marin-Gabriel MA, de las Heras-Ibarra S, Bergón-Sendin E, Baro-Fernández M, Sanz F, García-Martínez J, Ruíz-Contreras J. “Infección respiratoria por Chlamydia trachomatis en lactantes. Presentación clínica y evolución de 18 casos”. An Pediatr 2004;60:349-53-

  36. Numazaki K, Chiba S, Kogawa K, Umetsu M, Motoya H, Nakao T. “Chronic respiratory disease in premature infants caused by Chlamydia trachomatis”. J Clin Pathol 1986;39:84-88.

  37. Niida Y, Numazaki K, Ikehata M, Umetsu M, Motoya H, Chiba S: “Two full-term infants with Chlamydia trachomatis pneumonia in the early neonatal period.” Eur J Pediatr 1998, 157:950-1.

  38. Sollecito D, Midulla M, Bavastrelli M, Panero A, Marzetti G, Rossi D, et al. “Chlamydia trachomatis in neonatal respiratory distress of very preterm babies: biphasic clinical picture”. Acta Paediatr 1992;51:788-91.

  39. Black CM. “Current Methods of Laboratory Diagnosis of Chlamydia trachomatis Infections”. Clin Microbiol Rev 1997;10:160-84.

  40. Peterson EM. “Laboratory detection of Chlamydia trachomatis”. WJM 1997; 167:36.

  41. Dumornay W, Roblin PM, Gelling M, Hammerschlag MR, Worku M. “Comparison of a Chemiluminometric Immunoassay with Culture for Diagnosis of Chlamydial Infections in Infants”. J Clin Microbiol 1992;30:1867-69.

  42. Hammerschlag MR, Gelling M, Roblin PM, Kutlin A, Jule JE. “Treatment of neonatal chlamydial conjunctivitis with azithromycin”. Pediatr Infect Dis J. 1998;17:1049–1050.

  43. Solomon AW, Mohammed Z, Massae PA, Shao JF, Foster A, Mabey DC, “Peeling RW. Impact of mass distribution of azithromycin on the antibiotic susceptibilities of ocular Chlamydia trachomatis”. Antimicrob Agents Chemother. 2005 Nov;49(11):4804-6.

  44. Welsh LE, Gaydos CA, Quinn TC. “In vitro evaluation of activities of azithromycin, erythromycin, and tetracycline against Chlamydia trachomatis and Chlamydia pneumoniae.” Antimicrob Agents Chemother. 1992 Feb;36(2):291-4.

  45. Mourad A, Sweet RL, Sugg N, Schachter J. “Relative resistance to erythromycin in Chlamydia trachomatis”. Antimicrob Agents Chemother. 1980 Nov;18(5):696-8.

  46. Rumpianesi F, Morandotti G, Sperning R, Satta G, Cevenini R. “In vitro activity of azithromycin against Chlamydia trachomatis, Ureaplasma urealyticum and Enfermedades Infecciosas y Microbiología, vol. 34, núm. 3, julio-septiembre 2014 85 García Oropeza y cols. REPERCUSIÓN PERINATAL Y REPRODUCTIVA DE LA INFECCIÓN POR CHLAMYDIA TRACHOMATIS Y MYCOPLASMA

  47. Mycoplasma hominis in comparison with erythromycin, roxithromycin and minocycline”. J Chemother. 1993 Jun;5(3):155-8. Agacfidan A, Moncada J, Schachter J. “In vitro activity of azithromycin (CP-62,993) against Chlamydia trachomatis and Chlamydia pneumoniae”. Antimicrob Agents Chemother. 1993 Sep;37(9):1746-8.

  48. Reyna FJ, Flores MS, Morales MI, Garcìa RS, Ortiz IFJ. “Identificación de Ureaplasma urealyticum en liquido cefalorraquideo de recién nacidos con sospecha de neuroinfecciòn mediante la reacción en cadena de la polimerasa”. Revista de Enfermedades Infecciosas en Pediatría 2007;82:42-45.

  49. Gonzàlez VF “Micoplasmas genitales” en: Infecciones de Transmisión Sexual Casanova RG, Ortiz IFJ, Reyna FJ (ed) México DF, Editorial Alfil, pp 149-162.

  50. Black MC. “Current Methods of Laboratory Diagnosis of Chlamydia trachomatis Infections”. Clin Microbiol Reviews 1997;10:160-184.

  51. Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines. MMWR 2006;55, RR-11.




2020     |     www.medigraphic.com